Toviaz contains fesoterodine fumarate and is an extended-release tablet. Fesoterodine is a muscarinic receptor antagonist.
Toviaz® is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
Published Studies Related to Toviaz (Fesoterodine)
Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. [2011.11]
AIMS: To characterize the response to fesoterodine treatment for overactive bladder (OAB) in subjects who did or did not choose to dose escalate in a flexible-dose study... CONCLUSION: A rapid and robust response to fesoterodine 4 mg was demonstrated in non-escalators. Subjects who chose to dose escalate to fesoterodine 8 mg at week 2 showed significant improvement by week 12 versus baseline and week 2 (prior to escalation), as well as versus placebo. Dose escalation to 8 mg fesoterodine provided subjects with efficacy and tolerability similar to those who were satisfied with the 4-mg dose. Copyright (c) 2011 Wiley Periodicals, Inc.
Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. [2011.05]
CONCLUSION: The results provide evidence that patients receiving fesoterodine 4 mg for their OAB symptoms may expect to experience a response as early as 1 week after initiating treatment. One limitation is that, although 65% of subjects had received treatment with antimuscarinics before the study, whether subjects were dissatisfied with previous treatment and reasons for dissatisfaction were not collected. This might affect the magnitude of outcome improvements. Also, it is not known whether the UPS is sensitive enough to detect treatment differences as early as week 1.
Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptoms. [2011.05]
CONCLUSIONS: Long-term fesoterodine treatment was well tolerated and associated with sustained improvements in OAB symptoms in men and women.
Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. [2011.05]
OBJECTIVE: * To show the superior efficacy of fesoterodine over tolterodine extended release (ER) in a placebo-controlled overactive bladder (OAB) trial with predefined treatment comparisons for both diary measures and patient-reported outcomes... CONCLUSIONS: * In this randomized study, which is the largest to compare antimuscarinic efficacy performed to date, fesoterodine 8 mg was superior to tolterodine ER 4 mg for UUI episodes, micturitions and urgency episodes, as well as for self-reported patient assessments of bladder-related problems, urgency, symptom bother and health-related quality of life. * The superiority of fesoterodine 8 mg over tolterodine ER 4 mg was observed as early as 3 weeks after escalation from fesoterodine 4 mg for most outcomes. These data may have important implications for the clinical management of OAB patients previously treated with tolterodine ER. (c) 2010 THE AUTHORS. BJU INTERNATIONAL (c) 2010 BJU INTERNATIONAL.
Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. [2010.09.21]
Study Type - Therapy (RCT) Level of Evidence 1b OBJECTIVE: To show the superior efficacy of fesoterodine over tolterodine extended release (ER) in a placebo-controlled overactive bladder (OAB) trial with predefined treatment comparisons for both diary measures and patient-reported outcomes... CONCLUSIONS: In this randomized study, which is the largest to compare antimuscarinic efficacy performed to date, fesoterodine 8 mg was superior to tolterodine ER 4 mg for UUI episodes, micturitions and urgency episodes, as well as for self-reported patient assessments of bladder-related problems, urgency, symptom bother and health-related quality of life. The superiority of fesoterodine 8 mg over tolterodine ER 4 mg was observed as early as 3 weeks after escalation from fesoterodine 4 mg for most outcomes. These data may have important implications for the clinical management of OAB patients previously treated with tolterodine ER. (c) 2010 THE AUTHORS; BJU INTERNATIONAL (c) 2010 BJU INTERNATIONAL.
Clinical Trials Related to Toviaz (Fesoterodine)
An Open Label Study to Measure Efficacy of Fesoterodine (Toviaz) Post Surgery for Benign Prostatic Hyperplasia [Recruiting]
The subjects who have symptoms of overactive bladder (many trips to the bathroom, and
urgency with or without the inability to hold your urine until you get to the toilet) are
invited to participate in this research study. Overactive bladder is a common sequelae of
long-term bladder outlet obstruction in men. Unfortunately, it does not often resolve after
treatment of the obstruction (transurethral resection of the prostate). These patients are
usually started empirically on alpha-blockers or occasionally anticholinergic agents, former
used to treat enlarged prostate medically, and latter, to treat overactive bladder. We
hypothesize that these patients would be significantly improved with a long-acting
anticholinergic agent such as long acting Fesoterodine or Toviaz.
Earlier studies have shown that anticholinergic drugs seem to have a beneficial effect on
symptoms of patients with bladder outlet obstruction and overactive bladder. In addition,
anticholinergic drug Toviaz is not associated with increased incidence of complication like
acute urinary retention, a state where patient is unable to empty the bladder as an adverse
effect of the drug.
A large proportion of our patients that are undergoing treatment for bladder outlet
obstruction also have overactive bladder. We propose an open label trial to evaluate the
efficacy of Toviaz (fesoterodine) 4mg to 8 mg in patients that have continued symptoms of
overactive bladder one month following transurethral resection of the prostate. Toviaz is an
antimuscarinic and anticholinergic agent, and is a newer formulation of Detrol. Patients
with overactive bladder on urodynamic test preoperatively will be considered. If these
patients continue to have symptoms at the one-month post-operative visit, they will be
enrolled into the study. We expect a total of 25 patients to be enrolled within 4 months.
All patients will receive Toviaz 4mg to 8 mg. The patients will be followed at 3 months
post-op, 4 months post-op, and 7 months post-op. At each post-op visit, the patients will
fill out an AUA symptom score questionnaire, have noninvasive uroflowmetry performed, and
have a post-void residual measured by bladder scan. Using standard statistical analysis, we
will see if there is a difference in symptoms, post-void residual, or maximum flow rate
between baseline and 7 months post-op. We will continue the study to evaluate long-term
efficacy, dropout rate, and complications. An FDA approved flexible dosing regimen will be
allowed for the duration of the study.
Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive Bladder [Recruiting]
This is an open-label extension study intended for subjects who have previously completed
study A0221045 (fesoterodine in elderly OAB patients) and who have been recommended by the
investigator as being suitable for the extended use of Fesoterodine. Data from this study
will extend the evaluation of efficacy, tolerability and safety of Fesoterodine in older
subjects from Portugal.
A Study To Find Out How Fesoterodine Works In Children Aged 6 To 16 Years With Bladder Overactivity Caused By A Neurological Condition [Recruiting]
The objective of the study is to find out if the medicine fesoterodine is a useful treatment
in children with bladder muscle overactivity caused by a neurological condition. Children
will be aged 6 to 16 years old and weigh more than 25 kg (55 lb). This is done by finding
out how well it works, what the body does to fesoterodine, what side effects are experienced
and the safety of fesoterodine. It will be compared with the medicine oxybutynin, which is
already available for treating the condition.
Non-Interventional Study To Investigate Whether Information Provided To Patients Influences Their Satisfaction With Toviaz Therapy [Not yet recruiting]
Collect information on treatment with Toviaz(fesoterodine) under ordinary prescribing
conditions, and to investigate whether additional educational information affects
satisfaction with treatment as perceived by the patient.
Premarin Versus Toviaz for Treatment of Overactive Bladder [Recruiting]
The use of vaginal estrogen cream in conjunction with Toviaz will be more effective than the
use of Toviaz alone for the treatment of overactive bladder.
Reports of Suspected Toviaz (Fesoterodine) Side Effects
Drug Ineffective (164),
DRY Mouth (145),
Urinary Retention (58),
Urinary Incontinence (44),
Vision Blurred (44),
Malaise (29), more >>
Page last updated: 2011-12-09